Start-ups bent on determining the 3D structures of proteins are trying to figure out the best ways to package their capabilities and data for sale to drugmakers. Growing numbers of commercial and academic researchers are seeking information about proteins--in particular structural information that influences how these important actors of the body function, and how drugs may fit them. X-ray crystallography is the gold-standard way of getting structural information, and a number of start-ups are gearing up to use the method on a larger scale than ever before. They want to sell the data to drugmakers to use in drug discovery, or better yet, form alliances to obtain and leverage the data-whose value in quantity is as yet unproven. Business models are still evolving: early plans to create databases are fading as firms acknowledge it will take time to accumulate quantities of structures and drugmakers already deluged with data demand actionable information. Service models may suffice temporarily, but won't provide much return in the long-term. Small start-ups are focusing on determining structures of known targets, or new but simple ones, while other better-capitalized companies lay bigger plans: encouraging drugmakers to look at unknown targets and learn more broadly, or to utilize multiple crystals. All the firms are getting involved in screening as a means of lead discovery. Companies starting up in the field of structure-based drug design are competing in the marketplace not only with each other, but against the availability of public data, and other crystal-free methods of gaining information about proteins.
by Deborah Erickson
Now that the first draft of the human genome has been fully sequenced, along with the genomes of many other...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.
Korean firm’s head of research talks to Scrip about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential.
The Danish firm’s board unanimously supports a $2bn take-private offer by PE firms Nordic Capital and Permira. A revised offer would seek to bypass the opposition of a major shareholder.
The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.
The Danish firm’s board unanimously supports a $2bn take-private offer by PE firms Nordic Capital and Permira. A revised offer would seek to bypass the opposition of a major shareholder.
The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.
Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.
